Member-only story

ErSO-TFPy emerges as a groundbreaking innovation, offering a single-dose solution with the potential to revolutionize the therapeutic landscape of ERα+ breast cancer treatment.

Single-Dose ErSO-TFPy Eradicates Breast Cancer

ErSO-TFPy: A Paradigm Shift in Single-Dose Breast Cancer Therapy

Josh Universe
Biohackers Media
Published in
4 min readJan 25, 2025

--

Researchers have recently uncovered a novel small-molecule drug that has demonstrated remarkable efficacy in eradicating breast cancer in a single dose. This new therapeutic option could potentially hinder cancer recurrence and reduce the necessity for surgical interventions [1].

A conceptual representation of a novel, single-dose therapeutic approach targeting breast cancer cells. (Biohackers Media)

The Ongoing Fight Against Breast Cancer

While significant advancements have been made in breast cancer treatments, the battle is far from concluded. Approximately 70% of breast cancer cases are classified as estrogen receptor alpha positive (ERα+), indicating that the hormone estrogen propels the tumor’s growth. Contemporary therapies have successfully established a high five-year survival rate for patients diagnosed with ERα+ cancer; however, this achievement is contingent upon early detection, surgical resection, and subsequent long-term hormone therapy. The latter often presents serious…

--

--

Biohackers Media
Biohackers Media

Published in Biohackers Media

Biohackers Media is an independent and open source for longevity science & industry news & information by the International Biohacking Community.

Josh Universe
Josh Universe

Written by Josh Universe

Founder - International Biohacking Community, Transhumanist Council. Scientist-Astronaut Candidate. Writes about Space, Astronomy, Futurology, Longevity.

No responses yet